Jagsonpal Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals has submitted to the stock exchanges the annual disclosure under SEBI Regulation 31(4) for FY ended March 31, 2025. Two promoter groups — Infinity Holdings (along with persons acting in concert) and Rajpal Singh Kochhar / Aresko Progressive Private Limited — have declared that they did not create any encumbrance (pledge, charge, or lien) on their shares, directly or indirectly, during the financial year. This is a routine annual compliance filing confirming nil pledging activity by the promoters. The disclosure was signed by Infinity Holdings' director Mohammud Zaid Peerun and Aresko Progressive's Rajpal Singh Kochhar, dated April 1, 2025.
This is a neutral, routine compliance filing. No new pledge was created and no existing pledge was invoked or released, so there is no direct impact on stock price or shareholder risk from this announcement.